1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Biomarkers in Parkinsons Disease

Biomarkers in Parkinsons Disease

  • August 2014
  • -
  • Insight Pharma Reports

Overview

Biomarkers in Parkinson’s Disease is focused on the biomarker identification and development in patients with Parkinson’s Disease. As a spin-off of Biomarkers: Discovery and Development for a Diagnostic Approach to Neurodegenerative Disorders, this report focuses on the Parkinson’s Disease space featured in the parent report, highlighting several biomarker targets under investigation and the progress that has been made in the industry. With regards to employing the use of biomarkers for Parkinson’s Disease, Biomarkers in Parkinson’s Disease captures market growth of biomarkers, advantages, disadvantages, and validation techniques.

Experts interviewed in this report include:
Dr. Andrew West, Associate Professor of Neurology and Neurobiology and Co-Director, Center for Neurodegeneration and Experimental Therapeutics
Dr. Xuemei Huang, Professor and Vice Chair, Department of Neurology; Professor of Neurosurgery, Radiology, Pharmacology, and Kinesiology Director; Hershey Brain Analysis Research Laboratory for Neurodegenerative Disorders, Penn State University-Milton, S. Hershey Medical Center Department of Neurology
Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers

Also available in this report is extensive survey data exclusively conducted for this report. Illustrated by 30figures captured in an in-depth analysis, this section features insight into targets under investigation, challenges, advantages, and desired features of future diagnostic applications. To add even more to the robustness of this report, Insight Pharma Reports also garnered a table of clinical trial information and pipeline data related to Parkinson’s Disease. This table features companies, targets, clinical phases, and brief target/product descriptions.

Table Of Contents

Biomarkers in Parkinsons Disease
Table of Contents
Executive Summary

CHAPTER 1: The Focus of this Report

CHAPTER 2: Biomarkers and Their Clinical Utility
What are Biomarkers?
Advantages of Biomarkers
Clinical Endpoints vs. Surrogate Endpoints
Advantages of Biomarkers as Surrogate Endpoints
Disadvantages to Biomarkers as Surrogate Endpoints
How are Biomarkers Validated?
CHAPTER 3: Biomarkers in Neurodegenerative Disorders

CHAPTER 4: Parkinson's Disease
What is Parkinson's Disease?
Genetic Factors Linked to Parkinson's Disease
PARK2 (parkin/ubiquitin E3 ligase)
PINK1 (PTEN-induced kinase 1 protein)
GBA (glucocerebrosidase)
Promising Biomarkers for Parkinson's Disease
SNCA (?-synuclein)
PARK7 (DJ-1 protein)
LRRK2 (dardarin protein)
Other biomarkers
Interview with Dr. Andrew West
Research Background
LRRK2 Protein Kinase
Advantages
Challenges and Limitations
Parkinson's Disease Outlook
CHAPTER 5: Penn State Hershey Medical Center
Research Background
MRI for Parkinson's Disease Diagnosis
Interview with Dr. Xuemei Huang
Research Background
Non-Invasive Imaging Tool
Advantages
Challenges and Limitations
Parkinson's Disease Outlook
Atlantic Biomarkers
Research Background
Mass-Spectrometry Assays for Biomarkers
Impact on Healthcare
Interview with Dr. Andreas Jeromin
Company Background
Neurobiomarker Research
Mass Spectrometry-Based Assays
CHAPTER 6: Survey Results

CHAPTER 7: Clinical Trials and Pipeline Information in Parkinson's Disease

References

About Cambridge Healthtech Institute


Tables and Figures

Figure 2.1: Growth of Interest in Biomarkers
Figure 2.2: Biomarker Presence in Diagnostic Development vs. Therapeutic Development
Figure 3.1: Comparison of Disease Categories
Figure 3.2: Growth of Interest in Biomarkers for Neurology
Figure 3.3: Growth of Interest in Biomarkers for Parkinson's Disease
Figure 6.1: How Would You Categorize Your Organization?
Figure 6.2: Which Neurodegenerative Condition are You Currently Studying?
Figure 6.3: Which Targets for Huntington's Disease (HD) are You Currently Studying?
Figure 6.4: What is the Clinical Status of Your Target(s) for HD?
Figure 6.5: When Do You Expect Your Targets for HD to Enter Clinical Trials?
Figure 6.6: When Do You Expect Your Target to be an Available Therapeutic for HD?
Figure 6.7: Which Targets for Amyotrophic Lateral Sclerosis (ALS) are You Currently Studying?
Figure 6.8: What is the Clinical Status of Your Target(s) for ALS?
Figure 6.9: When Do You Expect Your Targets for ALS to Enter Into Clinical Trials?
Figure 6.10: When Do You Expect Your Target to be an Available Therapeutic for ALS?
Figure 6.11: Which Targets for Multiple Sclerosis (MS) are You Currently Studying?
Figure 6.12: What is the Clinical Status of Your Target(s) for MS?
Figure 6.13: When Do You Expect Your Targets for MS to Enter Into Clinical Trials?
Figure 6.14: When Do You Expect Your Target for MS to be an Available Therapeutic?
Figure 6.15: Which Signatures for Alzheimer's Disease (AD) are You Currently Studying?
Figure 6.16: What is the Clinical Status of Your Target(s) for AD?
Figure 6.17: When Do You Expect Your Targets for AD to Enter Into Clinical Trials?
Figure 6.18: When Do You Expect Your Target to be an Available Therapeutic for AD?
Figure 6.19: Which Signatures for Parkinson's Disease (PD) are You Currently Studying?
Figure 6.20: What is the Clinical Status of Your Target(s) for PD?
Figure 6.21: When Do You Expect Your Targets for PD to Enter Into Clinical Trials?
Figure 6.22: When Do You Expect Your Targets for PD to be an Available Therapeutic?
Figure 6.23: How Would You Describe Your Line of Research?
Figure 6.24: With Respect to Neurodiagnostics, Which Diagnostic Tools are You Developing for Biomarker Signatures?
Figure 6.25: With Respect to Neurodiagnostics, What are Challenges You Have Encountered with Your Diagnostic Development?
Figure 6.26: With Respect to Biomarker Development, What Tools are You Using to Identify Biomarker Signatures?
Figure 6.27: With Respect to Biomarker Development, What are Challenges You Have Encountered with Your Therapeutic Discovery/Development?
Figure 6.28: With Respect to Biomarker Therapeutics, What Tools are You Using to Identify Biomarker Signatures?
Figure 6.29: With Respect to Biomarker Therapeutics, What are Challenges You Have Encountered with Your Therapeutic Discovery/Development?
Figure 6.30: Which Imaging Techniques do You Feel are the Most Beneficial for Studying the Effects of Neurodegenerative Diseases?
Figure 6.31: Which Therapeutics do You Feel will be the Most Beneficial for Neurodegenerative Diseases?

Table 2.1: Clinical Applications of Biomarkers as Surrogate Endpoints

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Parkinson%s Disease  - Market Insights, Epidemiology and Market Forecast-2023

Parkinson%s Disease  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Parkinson’s Disease - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2025

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2025

  • $ 3995
  • Industry report
  • November 2016
  • by Global Data

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2025 Summary Schizophrenia is a severe mental disorder that affects an individual’s behaviors, thoughts, and emotions; it is extremely heterogeneous, ...

Parkinson%s Disease  - Epidemiology Forecast To 2023

Parkinson%s Disease  - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Parkinson's Disease  - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Parkinson's Disease  in seven major markets (US, France, Germany, Italy, Spain, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.